Under the primary base case analysis, annual mSEPT9 screening resulted in more Quality-adjusted-life-years gained (QALYG), CRC cases averted and CRC deaths averted than both annual FIT screening and ...

The FDA approved the first blood-based colorectal cancer test, Epi proColon, earlier this year. However, gastroenterologists are unsure if the benefits outweigh the costs for this new screening method ...

Blood-based colorectal cancer screening test Epi proColon was more cost-effective than other alternative screening options, according to a company release about a study published in the Journal of the ...

An FDA advisory panel voted by a narrow margin to recommend premarket approval for the Epi proColon (Epigenomics AG) colorectal cancer (CRC) test today. The Molecular and Clinical Genetics Panel of ...

Epigenomics AG has announced that Polymedco, Inc. reiterates its commitment to support Epi proColon(R) in the United States. Epi proColon(R) is Epigenomics' convenient blood-based test for colorectal ...

CE-marked test kit detects methylated DNA of SEPT9 in blood plasma. Epigenomics and Dateks agreed to a distribution deal for Epigenomics’ Epi proColon test in Turkey. Epi proColon is a CE-marked test ...

Epigenomics AG has announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s lead product, Epi proColon®, the first and only FDA-approved blood-based colorectal cancer ...

BERLIN, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), today reported on micro-simulation model results indicating that Epi proColon®, a colorectal cancer ...

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this ...

Berlin (Germany) and San Diego, CA (U.S.A.), September 2, 2021 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that a study recently published in BMC Cancer ...

BERLIN and SAN DIEGO, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that a study published by the NCI-sponsored cancer ...

Epigenomics AG, the German-American cancer molecular diagnostics company, has announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s lead product, Epi proColon®, the ...